| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Dec, 2023 | Sep, 2023 | Jun, 2023 |
| Sales | 0 | 0 | 210 | 180 | 250 |
| Sales Growth | unch | -100.00% | +16.67% | -28.00% | unch |
| Net Income | -5,080 | -5,000 | -5,180 | -6,300 | -8,250 |
| Net Income Growth | -1.60% | +3.47% | +17.78% | +23.64% | -25.76% |
Quantum Cyber N.V. (QUCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif.
Fiscal Year End Date: 12/31